Home > Boards > US Listed > Miscellaneous > Diffusion Pharmaceuticals Inc. (DFFN)

Hi wgg2,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Spideyboy Member Profile
 
Followed By 17
Posts 974
Boards Moderated 0
Alias Born 04/07/08
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2021 4:10:13 PM
Diffusion Pharmaceuticals Issues Letter to Shareholders GlobeNewswire Inc. - 9/9/2021 7:32:00 AM
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference GlobeNewswire Inc. - 9/8/2021 7:32:00 AM
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division GlobeNewswire Inc. - 8/30/2021 7:32:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2021 4:32:29 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/12/2021 4:51:05 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/11/2021 8:02:02 AM
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update GlobeNewswire Inc. - 8/11/2021 7:32:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/30/2021 4:34:34 PM
Diffusion Pharmaceuticals posts positive trend in oxygenation from TCOM trial Seeking Alpha - 6/30/2021 7:59:30 AM
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial GlobeNewswire Inc. - 6/30/2021 7:35:00 AM
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire Inc. - 6/28/2021 8:35:00 AM
Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 GlobeNewswire Inc. - 6/21/2021 8:35:00 AM
Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum GlobeNewswire Inc. - 6/21/2021 7:35:00 AM
Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting GlobeNewswire Inc. - 6/18/2021 7:35:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/20/2021 4:22:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/12/2021 7:30:54 AM
Diffusion Pharma gains 17% on final TSC data in hospitalized COVID-19 patients Seeking Alpha - 5/10/2021 8:05:58 AM
Diffusion Pharmaceuticals EPS misses by $0.02 Seeking Alpha - 5/10/2021 7:54:12 AM
Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 ... GlobeNewswire Inc. - 5/10/2021 7:50:00 AM
Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update GlobeNewswire Inc. - 5/10/2021 7:05:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2021 4:46:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2021 4:08:43 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2021 4:41:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/25/2021 7:14:22 PM
Spideyboy   Monday, 05/31/21 05:14:26 AM
Re: None
Post # of 3488 
Hi wgg2,

As requested, I just had a look at DFFN.

While I don't think there should be a problem with safety of the product, there otherwise is very little to go on to observe efficacy. Even at the highest level of 1.5mg/kg every 6 hours (0.25mg per hour on average), when we consider that this product is trying to increase essentially plasma permeability to oxygen molecules by 'organising water molecules' then there is an awful lot of water molecules in the cardiovascular system. I don't see how that amount of drug related to amount of water will have much of an effect. Not only that but the idea is to enhance the oxygen permeability close to hypoxic tissues, so that means that logically a very very small amount of the molecule will be present in the vasculature at the specific hypoxic tissue site, which I assume would further reduce the efficacy for that tissue.

The covid trial was not only small at 24 patients, but then, that itself was divided up into 4 cohorts. So I assume 6 in each. And no control. I don't really see the ability to come to any conclusions there. Essentially while the drug will probably do what it is designed for, it's not particularly complicated, just using a large hydrophobic chain, I would feel the dosage will likely need to be increased considerably to observe a therapeutic effect. I could be wrong though as in the limited pre-clin data in the company presentation, they apparently observed statistically significant effect in rats at 0.02mg/kg every 10 mins for 60 mins (0.12mg per hour average). So far we have seen, the human dosage of 1.5mg/kg, which is on an average bases 2x greater, was apparently starting to see a benefit.

Also thus far I don't see any information on half-life or clearance, so difficult to understand how much stays in the system for how long, which would of course have important impact on efficacy.

Additionally a quick google search found these 2 papers,
1 of them on dogs, found that a dose of 0.1mg/kg had no effect in hypoxia.
No effect of trans sodium crocetinate on maximal O(2) conductance or V(O(2),max) in moderate hypoxia
https://pubmed.ncbi.nlm.nih.gov/12660103/

Then in this human study in PAD, they present it in a positive light, but the sample again is low and sub-divided into even smaller samples. So I don't feel it is reliable. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182020/

That's all I can say for now.

It will be very important to see efficacy from decent sized cohorts before being able to be clear to see any signal. And again dosage I feel will need to be considerably higher. I don't know how high the dosage will be allowed to go.

Best,
Spidey

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences